Bank of Nova Scotia bought a new stake in Humana Inc. (NYSE:HUM - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 257,575 shares of the insurance provider's stock, valued at approximately $102,314,000. Bank of Nova Scotia owned 0.21% of Humana as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in HUM. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Humana by 4.1% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 250,330 shares of the insurance provider's stock valued at $66,207,000 after acquiring an additional 9,960 shares during the period. Sustainable Insight Capital Management LLC boosted its position in Humana by 23.7% during the 4th quarter. Sustainable Insight Capital Management LLC now owns 24,757 shares of the insurance provider's stock worth $6,341,000 after acquiring an additional 4,740 shares during the period. Pzena Investment Management LLC bought a new position in shares of Humana in the second quarter worth $1,749,014,000. Swedbank AB raised its stake in shares of Humana by 6.2% in the 4th quarter. Swedbank AB now owns 111,803 shares of the insurance provider's stock worth $28,636,000 after buying an additional 6,534 shares in the last quarter. Finally, North Dakota State Investment Board acquired a new stake in Humana in the 4th quarter valued at about $1,517,000. 92.38% of the stock is owned by institutional investors.
Analysts Set New Price Targets
HUM has been the topic of a number of recent analyst reports. Weiss Ratings raised Humana from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, August 14th. Raymond James Financial lowered shares of Humana from an "outperform" rating to a "market perform" rating in a research report on Thursday, July 30th. Jefferies Financial Group upgraded shares of Humana from a "buy" rating to a "buy" rating in a report on Wednesday, May 20th. Zacks Research downgraded shares of Humana from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 11th. Finally, Cantor Fitzgerald upped their price objective on shares of Humana from $264.00 to $300.00 and gave the company a "neutral" rating in a research note on Tuesday, July 7th. Fourteen analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $395.22.
Check Out Our Latest Stock Report on Humana
Humana Price Performance
NYSE HUM opened at $379.22 on Friday. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The stock's 50-day moving average is $383.38 and its two-hundred day moving average is $281.59. The firm has a market cap of $45.54 billion, a P/E ratio of 35.88, a price-to-earnings-growth ratio of 2.17 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts' consensus estimates of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The business had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. During the same quarter in the prior year, the firm posted $6.27 EPS. The firm's revenue for the quarter was up 26.2% on a year-over-year basis. On average, analysts anticipate that Humana Inc. will post 9.08 earnings per share for the current fiscal year.
About Humana
(
Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
